Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

Journal：stroke

Publication type: Article

IF(IF): 7.914

PMID: 31726963 Link To Pubmed Full text Download

Subgroup analysis of CHANCE gene showed that CYP2C19 gene variation significantly affected the efficacy of dual antibody therapy. According to previous studies, body weight and body mass index has significant effect on antiplatelet efficacy. Some researches argued that this phenomenon may be due to increased platelet activity in overweight or obese patients, and another reason may be that the metabolism of antiplatelet drugs is faster in overweight population. Whether body mass index has an effect on the association between CYP2C19 genetic variants and dual antiplatelet efficacy is not clear. We hypothesized that in patients with high BMI, the efficacy of dual antiplatelet therapy may be affected in spite of CYP2C19 is functional. This study is aim to estimate the influence of body mass index on the association between CYP2C19 genetic variants and dual antiplatelet efficacy among patients with minor stroke and TIA.

Patients from the CHANCE trial were involved in this substudy and successfully genotyped for both two single-nucleotide polymorphisms (SNPs) of CYP2C19 (*2 and *3). Cox proportional risk regression model was used to evaluate the interactions between CYP2C19 loss-of-function allele (*2 and *3) carrier status and dual antiplatelet efficacy stratified by body mass index.